Watch INDV. Know when insiders buy.
One email the day a filing lands. Free.
Work order
59
WATCH · insiders 58, shorts 60
Insiders, 90 days
+$54K
net buying · 1 buy, 0 sells
Congress, 90 days
0 / 0
no disclosures naming it
Big money
0 / 15
none of the tracked funds disclose it
Calls on record
0
nobody we score has called it yet
MKT CAP $4.1BP/E 12.5DIV YIELD —FCF YIELD -2.69%REV TTM $1.3B +13.5%NET INCOME $355M +228.7%NET DEBT $265M52W 22.51 – 41.83NEXT EARNINGS Nov 5 EST.SEC XBRL · TTM TO Invalid Date
Financials
By quarter
| Period | Revenue | YoY | Gross margin | Operating income | Net income | YoY | EPS | Op. cash flow | Capex | Free cash flow | Filed |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Q2 2026 · Jun 30 | $343M | +13.6% | 85.7% | $160M | $122M | +577.8% | 0.98 | $229M | $7M | $222M | Aug 3 |
| Q1 2026 · Mar 31 | $317M | +19.2% | 87.4% | $137M | $89M | +89.4% | 0.69 | −$9M | $20M | −$29M | Aug 3 |
| Q4 2025 · Dec 31derived | $358M | +19.7% | 81.6% | $81M | $102M | +385.7% | 0.79 | −$221M | $24M | −$245M | Feb 26 |
| Q3 2025 · Sep 30 | $314M | +2.3% | 73.2% | $43M | $42M | +90.9% | 0.33 | −$39M | $20M | −$59M | Oct 30 |
| Q2 2025 · Jun 30 | $302M | +1.0% | 82.8% | $72M | $18M | — | 0.14 | $158M | $17M | $141M | Aug 3 |
| Q1 2025 · Mar 31 | $266M | −6.3% | 83.1% | $66M | $47M | −23.0% | 0.38 | $75M | $5M | $70M | Aug 3 |
| Q4 2024 · Dec 31 | $299M | — | 83.6% | $46M | $21M | — | 0.16 | −$17M | $16M | −$33M | Feb 26 |
| Q3 2024 · Sep 30 | $307M | — | 78.5% | $35M | $22M | — | 0.16 | $2M | $7M | −$5M | Feb 26 |
| Q2 2024 · Jun 30 | $299M | — | 73.6% | −$118M | −$97M | — | -0.72 | $88M | $4M | $84M | Feb 26 |
| Q1 2024 · Mar 31 | $284M | — | 86.6% | $75M | $61M | — | 0.45 | −$37M | $2M | −$39M | Feb 26 |
By fiscal year
| Year | Revenue | Gross margin | Operating income | Net income | Net margin | EPS | Op. cash flow | Capex | Free cash flow | Buybacks | Dividends paid |
|---|---|---|---|---|---|---|---|---|---|---|---|
| FY2025 · to Dec 31 | $1.2B | 80.2% | $262M | $210M | 16.9% | 1.64 | −$27M | $66M | −$93M | $11M | — |
| FY2024 · to Dec 31 | $1.2B | 80.6% | $38M | $7M | 0.6% | 0.05 | $36M | $29M | $7M | $173M | — |
| FY2023 · to Dec 31 | $1.1B | 84.1% | −$152M | −$126M | -11.5% | -0.92 | −$300M | $8M | −$308M | $33M | — |
| FY2022 · to Dec 31 | $901M | 83.1% | −$77M | −$42M | -4.7% | -0.30 | −$4M | $5M | −$9M | $90M | — |
Every number comes from Indivior Pharmaceuticals, Inc.'s own XBRL-tagged filings with the SEC, not a data vendor. Quarters marked derived are the fiscal year minus the three reported quarters, the same way every data provider computes Q4. Restated figures replace originals as later filings arrive.